Literature DB >> 8244962

Differential acute-phase response of rat kininogen genes involves type I and type II interleukin-6 response elements.

H M Chen1, W S Liao.   

Abstract

The serum concentration of rat T1 kininogen increases 20-30-fold in response to acute inflammation. This increase, induced in the liver, is regulated primarily at the transcriptional level. In contrast, synthesis of a homologous K kininogen is not induced. In this study, we further analyzed a 321-base pair interleukin (IL)-6 response element in the T1 kininogen promoter and showed that it consists of at least three functionally distinct sequences (A, B, and C boxes). All three sequences were required for full promoter activity. The B box, a strong C/EBP-binding site, was crucial for T1 kininogen's basal expression, whereas A and C boxes resembled the type II IL-6 response elements and were critical for the cytokine response. C/EBP alpha, -beta, and -delta interacted with the B box sequence; however, upon IL-6 stimulation, C/EBP delta binding activity was dramatically induced and became the predominant factor binding to this site. Consistent with these binding studies were the cotransfection experiments, revealing that C/EBP delta was the most potent transactivator under induced conditions and that its transactivation on the T1 kininogen promoter required an intact B box. These findings substantiated the importance of the B box in eliciting the full acute-phase response. A sequence comparison showed the K kininogen promoter contained identical A and B boxes but differed from the T1 kininogen promoter by two nucleotides at the C box. This divergence reduced the IL-6 response by approximately 4-fold, thus contributing to the differential inflammatory response. Our studies demonstrate that evolutionary divergence of a few nucleotides at a critical sequence in the promoter regions can profoundly alter the expression patterns of downstream genes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8244962

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  STAT3/NF-κB interactions determine the level of haptoglobin expression in male rats exposed to dietary restriction and/or acute phase stimuli.

Authors:  Aleksandra Uskoković; Svetlana Dinić; Mirjana Mihailović; Nevena Grdović; Jelena Arambašić; Melita Vidaković; Desanka Bogojević; Svetlana Ivanović-Matić; Vesna Martinović; Miodrag Petrović; Goran Poznanović; Ilijana Grigorov
Journal:  Mol Biol Rep       Date:  2011-05-10       Impact factor: 2.316

2.  Increased C-reactive protein in ACE-inhibitor-induced angioedema.

Authors:  M Bas; T K Hoffmann; H Bier; G Kojda
Journal:  Br J Clin Pharmacol       Date:  2005-02       Impact factor: 4.335

3.  Expression of kininogens in the connective tissue-type mast cells of the rat.

Authors:  K Hosoi; S Matsuura; K Tsumura; W Wei; M N Parvin; J Tada; T Akamatsu; N Kanamori; K Suzuki
Journal:  Immunology       Date:  2000-12       Impact factor: 7.397

4.  C/EBPalpha is critical for the neonatal acute-phase response to inflammation.

Authors:  B L Burgess-Beusse; G J Darlington
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

5.  Induction of the mouse serum amyloid A3 gene by cytokines requires both C/EBP family proteins and a novel constitutive nuclear factor.

Authors:  J H Huang; W S Liao
Journal:  Mol Cell Biol       Date:  1994-07       Impact factor: 4.272

6.  Requirement for nuclear factor kappa B signalling in the interleukin-1-induced expression of the CCAAT/enhancer binding protein-delta gene in hepatocytes.

Authors:  Saira Ali; Nishi N Singh; Hatice Yildirim; Dipak P Ramji
Journal:  Int J Biochem Cell Biol       Date:  2009-09-30       Impact factor: 5.085

7.  Curdlan sulphate modulates protein synthesis and enhances NF-kappaB and C/EBP binding activity in HepG2 cells.

Authors:  A Guzdek; H Rokita
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

8.  Angioedema, ACE inhibitor and COVID-19.

Authors:  Ekjot Grewal; Bayu Sutarjono; Ibbad Mohammed
Journal:  BMJ Case Rep       Date:  2020-09-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.